← FDA DRUG APPROVALS

FDA ANDA · ANDA203080

NEVIRAPINE

Sponsor: MICRO LABS LTD

APPLICATION
ANDA203080
TYPE
ANDA
ORIGINAL APPROVAL
2012-05-22
LATEST ACTION
2024-05-23
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

NEVIRAPINEPrescription
NEVIRAPINE 200MG · TABLET · ORAL

Approval history

2024-05-23Labeling · Supplement 4 · standardAP
2020-07-21Labeling · Supplement 2 · standardAP
2020-07-21Labeling · Supplement 3 · standardAP
2012-05-22UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →